WCA-814
WCA-814 is an androgen receptor (AR) antagonist-Hsp90 inhibitor conjugate. WCA-814 induces the degradation of full-length and AR-V7. WCA-814 has cytotoxic effect in prostatic cancer cells (IC50: 171.2 nM, 26.5 nM for LNCaP, 22Rv1 cell).
For research use only. We do not sell to patients.
- CAS No.: 2951858-45-8
- Formula: C46H53ClN10O5
- Molecular Weight:861.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CWR22R | IC50 |
26.5 nM
Compound: 6; WCA-814
|
Cytotoxicity against human 22Rv1 cells assessed as inhibition of cell growth incubated for 5 days in presence of AR agonist, R1881 by WST-1 assay
Cytotoxicity against human 22Rv1 cells assessed as inhibition of cell growth incubated for 5 days in presence of AR agonist, R1881 by WST-1 assay
|
[PMID: 36960664] |
| LNCaP | IC50 |
171.2 nM
Compound: 6; WCA-814
|
Cytotoxicity against AR-positive human LNCaP cells assessed as inhibition of cell growth incubated for 5 days in presence of AR agonist, R1881 in charcoal stripped serum by WST-1 assay
Cytotoxicity against AR-positive human LNCaP cells assessed as inhibition of cell growth incubated for 5 days in presence of AR agonist, R1881 in charcoal stripped serum by WST-1 assay
|
[PMID: 36960664] |
Chemical Information
-
CAS No. 2951858-45-8
-
Molecular Weight 861.43
-
Formula C46H53ClN10O5
-
SMILES
CC(C1=C(C=C(C(C2=NNC(N2C3=CC=C(C=C3)CN4CCN(CC4)CC5CCN(CC5)C6=CC=C(N=N6)C(N[C@H]7CC[C@@H](CC7)OC8=CC(Cl)=C(C=C8)C#N)=O)=O)=C1)O)O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)